Welcome reception

Welcome & introduction
Meeting Chairs: Claire Harrison & Amer Zeidan

Session 1: Challenging and uncommon scenarios in MPN (part I)
Chairs: Claire Harrison & Nicola Polverelli

• Young patients: Marta Sobas
• Pregnancy in MPN: Susan Robinson
• Skin cancer: Jon Lambert

Panel discussion

Session 2: Challenging and uncommon scenarios in MPN (part II)
Chairs: Andreas Reiter & Deepti Radia

• Transplantation for rare MPN: Nicola Polverelli
• Management of eosinophilia: Andreas Reiter
• Management of indolent systemic mastocytosis – a case-based discussion: Deepti Radia

Panel discussion

Break

Session 3: Novel approaches to upfront management of MF (part I)
Chairs: Haifa Kathrin Al-Ali & Adam Mead

• Classification and risk stratification: Alessandro Vannucchi
• When should a low-risk patient be treated and with what?: Prithviraj Bose
• What is a suboptimal responder?: Donal McLornan

Panel discussion

Session 4: Novel approaches to upfront management of MF (part II)
Chairs: Lucia Masarova & Prithviraj Bose

• Selinexor: Claire Harrison
• Updates on JAK inhibitors & JAKi-naïve studies: Prithviraj Bose
• Pelabresib: Adam Mead
• Navtemadlin: Haifa Kathrin Al-Ali

Panel discussion

Lunch

Session 5: Updates on new therapies (part I)
Chairs: David Steensma & Firas El Chaer

• Interferon: Jan Bewersdorf
• Imetelstat: Alessandro Vannucchi
• Nuvisertib: Firas El Chaer
• Elritercept: Claire Harrison
• Tagraxufusb in MF: Abdulraheem Yacoub

Panel discussion

Session 6: Updates on new therapies (part II)
Chairs: Bethan Psaila & Shahram Kordasti

• Targeting mutant CALR: Bethan Psaila
• Updates with hepicidin targets in PV: Marina Kremyanskaya
• Type 2 or mutation specific JAKi: David Steensma
• Targeting inflammation – lessons from MDS: Shahram Kordasti

Panel discussion

Break

Session 7: Novel thoughts on blastic phase and transplantation
Chairs: Adam Mead & Donal McLornan

• Diagnosis and risk stratification of AP and BP: Adam Mead
• New insights to the biology of leukaemic transformation in MPN: Charlotte Brierley
• Options for management of accelerated and blast phase: Should they be treated in the same way and how should we incorporate BMT? Donal McLornan
• Transplant for MF: Juan Carlos Hernández-Boluda

Panel discussion

Day 1 wrap up
Claire Harrison

Welcome reception

Welcome to Day 2
International Consortium for MDS (icMDS): Current status and future vision: Amer Zeidan

Keynote talk 1
Immunome in prognostication and immune interventions management in MDS: Shahram Kordasti

Session 8: MDS classification and risk stratification
Chairs: Uma Borate & Luca Lanino

• Molecular classification of MDS: Robert Hasserjian
• Roadmap for harmonization of classifications of myeloid malignancies: The icMDS recommendations: Luca Lanino
• Consistent trial design for MDS clinical trials – the icMDS recommendations: Uma Borate
• Consistent trial design for CHIP and CCUS clinical trials – the icMDS recommendations: Zoey Xie
• AI in classification and risk stratification of MDS: Adrián Mosquera Orgueira

Panel discussion

Break

Session 9: Translational advances
Chairs: Valeria Santini & Klaus Metzeler

• Genetic characterization of therapy-relayed myeloid malignancies: Francesc Sole
• Clonal hematopoiesis in CAR T recipients, clinical relevance and risk for therapy-associated MDS: Klaus Metzeler
• Cardiovascular health in MPN patients: Alexander Lyon

Panel discussion

Session 10: Defining response criteria in MDS
Chairs: Lisa Pleyer & Rami Komrokji                           

• An update on response assessment in MDS: Lisa Pleyer
• Should MRD be an endpoint in the assessment of MDS?: Arjan Van De Loosdrecht
• Should CR be achieved before alloBMT for HR-MDS? Maximilian Stahl
• How to define disease modification in LR-MDS: Rami Komrokji

Panel discussion

Lunch

Session 11: TP53-mutated MDS
Chairs: Amer Zeidan & Thomas Cluzeau                                                                                             

• How should TP53-mutated MDS be classified?: Matteo Della Porta
• TP53-mutated MDS targeting – New directions: Thomas Cluzeau
• Novel insights on TP53-mutated MDS: An icMDS VALIDATE analysis: Tariq Kewan

Panel discussion

Session 12: Novel pathways and therapeutic targets in MDS
Chairs: Valeria Santini & Amy DeZern

• Updates on the biology of telomerase inhibition in MDS: Valeria Santini
• Is there a pathway forward for RARA agonists in MDS?: Amy DeZern
• Updates on PK agonists and HIF pathway targeting in MDS: Amer Zeidan
• Updates on TGF pathway modulation in MDS: Hetty Carraway

Panel discussion

Break

Session 13: iwMDS 2025: Lifetime achievement awards
Chairs: Amer Zeidan & Valeria Santini      

• Introduction for Ghulam Mufti: David Steensma
• An incredible mentor: Ghulam Mufti
• Introduction for Pierre Fenaux: Lionel Ades
• MDS and CMML. What has really improved over the years?: Pierre Fenaux

Keynote talk 2
Chair: Amer Zeidan

• Relevant endpoints for drug approvals for MDS and CMML: An FDA perspective: Dianne Pulte (FDA)

Panel discussion
Discussants: Amer Zeidan, David Steensma, Dianne Pulte (FDA) & Nina Kim (FDA)

Day 2 wrap up
Amer Zeidan

Group photo
All attendees

Faculty dinner

Welcome to Day 3
Amer Zeidan

Keynote talk 3
Updates on QoL and PRO assessment in MDS: the icMDS recommendations: Fabio Efficace

Session 14: Evolving strategies in the management of lower-risk MDS
Chairs: Andrew Brunner & Mikkael Sekeres     

• What do we know about luspatercept + ESA combinations for LR-MDS? Lionel Ades
• How do I sequence imetelstat in MDS?: Mikkael Sekeres
• Standardized reporting of MDS clinical trials – The icMDS recommendations: Andrew Brunner

Panel discussion

Session 15: Advancements in targeted therapies and immunomodulation in MDS
Chairs: Amer Zeidan & Marie Sebert        

• IRAK inhibitors in MDS – What’s next?: Anne Sophie Kubasch
• An update on immune checkpoint use in MDS/AML: Amer Zeidan
• Venetoclax in MDS: Yazan Madanat
• IDH inhibitors for MDS: Marie Sebert
• An update on oral hypomethylating agents in MDS – what’s next?: Elizabeth Griffiths

Panel discussion

Break

Session 16: Controversies in transplant for MDS
Chairs: Coleman Lindsley & Katharina Götze

• TP53 HR-MDS – Should you transplant or not?: Coleman Lindsley
• Recommendations for transplant for MDS in 2025: Carmelo Gurnari
• Current situation of allogeneic transplantation for MDS in Japan: Yasushi Miyazaki
• Outcome for patients with MDS/MPN undergoing allogeneic stem cell transplantation: An analysis of >300 patients across 12 German centers: Katharina Götze

Panel discussion

Session 17: Global perspectives on MDS trials – Clinical trials and real-world evidence
Chairs: Amer Zeidan & Valeria Santini       

• MDS trials in China: Bing Li
• MDS trials in France: Lionel Ades
• MDS trials in Italy: Valeria Santini
• MDS trials in Spain: Adrián Mosquera Orgueira
• MDS research in Greece: Hellenic experience: Ioannis Kotsianidis
• Scandinavian MDS research efforts: Astrid Olnes

Panel discussion

Meeting summary and close
Amer Zeidan